Company profile: Ausper Bio
1.1 - Company Overview
Company description
- Provider of biotechnology therapies developing ASO and oligonucleotide-conjugate drugs for chronic hepatitis B and other major infectious diseases, featuring AHB-137 (Phase I) targeting a conserved HBV mRNA region with potential HBsAg reduction and favorable safety, and Med-Oligo platforms that enhance ASO potency and safety, combining small molecule and antibody expertise.
Products and services
- Med-Oligo™ Technology Platform: A modular platform that architects ASO therapeutics with targeted chemical modifications to boost potency and safety, initially focused on HBV cure and extended to other chronic diseases
- AHB-137: A clinical-stage ASO that targets a conserved HBV mRNA region, showing potential for significant HBsAg reduction with a favorable safety profile in Phase I trials
- Med-Oligo™ with Conjugation: A conjugate-enabled platform that produces oligonucleotide therapeutics for chronic diseases by combining small‑molecule drug discovery and antibody development expertise.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ausper Bio
MaxThera
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of new treatments for bacterial infections, especially those caused by drug-resistant bacteria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MaxThera company profile →
Lumora
HQ: United Kingdom
Website
- Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumora company profile →
GNA Biosolutions
HQ: Germany
Website
- Description: Provider of molecular diagnostic technology using Pulse Controlled Amplification to combine ultrafast nucleic acid amplification with intrinsic sample preparation, enabling solutions for laboratory, on-site and point-of-care testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GNA Biosolutions company profile →
Pherecydes Pharma
HQ: France
Website
- Description: Provider of innovative biotechnology focused on developing personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and has launched a multicenter European phage therapy trial to evaluate treatment on infected burn wounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherecydes Pharma company profile →
Gritstone Bio
HQ: United States
Website
- Description: Provider of immunotherapies for cancer and infectious diseases, including GRANITE, a personalized neoantigen vaccine for solid tumors; SLATE, an off-the-shelf shared-neoantigen immunotherapy for KRAS-driven tumors; CORAL, prophylactic vaccines using self-amplifying mRNA; an HIV vaccine collaboration with Gilead; and EDGE, an AI platform to identify T cell targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gritstone Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ausper Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ausper Bio
2.2 - Growth funds investing in similar companies to Ausper Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ausper Bio
4.2 - Public trading comparable groups for Ausper Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →